Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 12/20 | 0.53 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 2/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5086724 | 0.78 | MGLL (0.72) | MGLLTLR9FAAHTDP1MAPT | |
| SCHEMBL29510657 | 0.78 | TLR9 (0.61) | MGLLTLR9FAAHTDP1L3MBTL1 | |
| SCHEMBL663870 | 0.78 | TLR9 (0.61) | MGLLTLR9FAAHTDP1L3MBTL1 | |
| SCHEMBL12313392 | 0.75 | TAAR1 (0.43) | TDP1L3MBTL1CES1 | |
| SCHEMBL25771233 | 0.72 | GABRA1 (0.46) | — | |
| SCHEMBL1535499 | 0.70 | MGLL (1.00) | MGLLTLR9FAAHTDP1MAPT | |
| SCHEMBL29510771 | 0.70 | MGLL (1.00) | MGLLTLR9FAAHTDP1MAPT | |
| SCHEMBL3870977 | 0.69 | MGLL (0.58) | MGLLTLR9FAAHTDP1 | |
| SCHEMBL24911005 | 0.69 | CA2 (0.41) | TDP1 | |
| SCHEMBL13856265 | 0.69 | TAAR1 (0.39) | TDP1L3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060223875-A1 | Methods and compositions for production, formulation and use of 1-aryl-3-azabicyclo[3.1.0]hexanes | DOV PHARMACEUTICAL, INC. | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223875-A1 | Methods and compositions for production, formulation and use of 1-aryl-3-azabicyclo[3.1.0]hexanes | HTR1B, SLC6A3, CYP1B1 | MGLL 2457/4885TLR9 2515/4885FAAH 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.